We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00287066
First Posted: February 6, 2006
Last Update Posted: February 21, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pfizer
February 2, 2006
February 6, 2006
February 21, 2008
February 2006
Not Provided
18F-labeled glucose uptake in muscle
Same as current
Complete list of historical versions of study NCT00287066 on ClinicalTrials.gov Archive Site
Glucose turnover overnight Insulin pharmacokinetics
Same as current
Not Provided
Not Provided
 
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
Open-Label Randomized Two-Way Crossover Pilot Study To Estimate The Effects Of Inhaled Versus IV Infusion Of Human Insulin With Regards To Glucose Disposal In Subjects With Type 1 Diabetes Mellitus
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
The study was terminated on Oct. 28, 2007. The protocol was undergoing implementation and methodological issues with major revisions that qualified this trial as a new trial. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Diabetes Mellitus
  • Drug: Inhaled Human Insulin
  • Drug: Regular Human Insulin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
22
March 2007
Not Provided

Inclusion Criteria:

  • Diabetes mellitus Type 1

Exclusion Criteria:

  • Asthma, COPD
  • Smoking
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00287066
A2171060
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP